Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Piramal Pharma Limited operates as a pharmaceutical company in North America, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the spectrum of the drug life cycle, including discovery, development, and commercial manufacturing of drug substances and products; complex hospital generics business which offers inhalation anesthetics, intrathecal therapy for spasticity management, injectable pain and anesthesia drugs, and other generic and specialty products; and India consumer healthcare business comprising analgesics, skin care, vitamin/mineral supplement, kids' wellness, digestives, women's health, and hygiene and protection. The company was incorporated in 2020 and is based in Mumbai, India.

Revenue projections:

Revenue projections for PPLPHARMA
Revenue projections for PPLPHARMA

Investors may react cautiously to news that Piramal Pharma Limited's revenues are forecasted to be lower than last year's. Such declines are likely to have a negative effect on the company's bottom line, which can lead to concerns about profitability and hinder investor confidence in the company's future performance.

Financial Ratios:

currentRatio 1.43100
forwardPE 55.60584
debtToEquity 60.08300
earningsGrowth 0.00000
revenueGrowth -0.08800
grossMargins 0.61046
operatingMargins -0.02160
trailingEps -0.18000
forwardEps 0.00000

PPLPHARMA's current ratio being 1.431 suggests that it has more than enough liquidity to cover short-term debt obligations. The company's cash reserves and current assets are sufficient to meet immediate liabilities, signaling solid financial health and minimal risk.
PPLPHARMA's forward PE is elevated, which may cap future price gains and even lead to a price correction. This overvaluation risk highlights the importance of considering this metric carefully in combination with other fundamental indicators to evaluate the stock properly.
PPLPHARMA's low earnings and revenue growth suggest that the company's profits may shrink. This trend could indicate underlying financial struggles and pose challenges for PPLPHARMA's future profitability.

Price projections:

Price projections for PPLPHARMA
Price projections for PPLPHARMA

PPLPHARMA's price projections have been steadily revised down, pointing to declining confidence in the company's outlook. This suggests that analysts are becoming more conservative in their expectations for PPLPHARMA's future performance.

Recommendation changes over time:

Recommendations trend for PPLPHARMA
Recommendations trend for PPLPHARMA


A recent buy bias from analysts toward PPLPHARMA may inspire confidence in investors, who could view the stock as a promising investment. This positive sentiment suggests that PPLPHARMA might be an appealing option for those looking to grow their wealth through stock market investments.